Quince Therapeutics (NASDAQ:QNCX) Receives New Coverage from Analysts at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a report published on Tuesday morning, Benzinga reports. The brokerage issued a buy rating and a $11.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd.

Quince Therapeutics Stock Up 19.0 %

Shares of Quince Therapeutics stock opened at $1.18 on Tuesday. The business has a 50-day moving average price of $0.77 and a 200 day moving average price of $0.80. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $1.43. The firm has a market cap of $50.99 million, a P/E ratio of -1.55 and a beta of 0.86. The company has a quick ratio of 6.15, a current ratio of 6.15 and a debt-to-equity ratio of 0.29.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter.

Insider Activity

In related news, CEO Dirk Thye purchased 77,500 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The shares were acquired at an average price of $0.69 per share, with a total value of $53,475.00. Following the acquisition, the chief executive officer now owns 766,941 shares in the company, valued at approximately $529,189.29. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Dirk Thye acquired 77,500 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The shares were acquired at an average price of $0.69 per share, with a total value of $53,475.00. Following the acquisition, the chief executive officer now directly owns 766,941 shares in the company, valued at approximately $529,189.29. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Charles S. Ryan acquired 48,387 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was purchased at an average price of $0.65 per share, for a total transaction of $31,451.55. Following the completion of the transaction, the president now owns 122,461 shares in the company, valued at $79,599.65. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 158,887 shares of company stock valued at $105,609. 16.80% of the stock is currently owned by insiders.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.